Center of Research in Therapeutic Innovation Suely Galdino (NUPIT SG) Biosciences Center Universidade Federal de Pernambuco (UFPE) Recife Pernambuco Brazil
Auto-generated profile, based on publicly available information
Thaynara Paula Warren Bezerra
Center of Research in Therapeutic Innovation Suely Galdino (NUPIT SG) Biosciences Center Universidade Federal de Pernambuco (UFPE) Recife Pernambuco Brazil
A nanotecnologia é uma área da ciência responsável pelos estudos sobre sistemas estruturados em escala nanométrica. No campo farmacêutico, os nanocarreadores têm sido investigados como veículo de fármacos na síntese de medicamentos inovadores para solucionar dificuldades em relação a biodisponibilidade, estabilidade e toxicidade. As formulações farmacêuticas nanoestruturadas são capazes de controlar a liberação das moléculas e ainda direciona essas moléculas para seu local específicos de ação e, assim maximizar os efeitos benéficos da terapia, como também auxilia na redução dos efeitos adversos. Vários estudos vêm evidenciando excelentes resultados na eficácia terapêutica de nanocarreadores empregados na elaboração de novos fármacos. Ademais, estes nanofarmacos disponibilizam inúmeras vantagens quando comparado com as formas farmacêuticas convencionais. O presente trabalho tem como objetivo, realizar uma revisão integrativa da literatura sobre a empregabilidade da nanotecnologia no desenvolvimento de novos fármacos, discutindo sobre os principais nanocarreadores que podem ser utilizados para a obtenção de fármacos, como: lipossomas, nanopartículas poliméricas, nanopartículas lipídicas, dendrímeros e ciclodextrinas. Foram utilizados 31 artigos que passaram pelos critérios de inclusão, que exigiam artigos acadêmicos com o idioma em português, inglês, espanhol e chinês, publicados nos últimos cinco anos retroativos. Diante dos estudos realizados pelos autores, conclui-se que a nanotecnologia quando aplicada na produção de fármaco é bastante eficiente pois possibilita uma melhorar significativa nas suas propriedades farmacocinéticas resultando um tratamento seguro e efetivo ao paciente.
The therapy to treat the Human Immunodeficiency virus (HIV) and decrease the viral load has been a challenge since its discovery due to its ability to mutate, escape from drug therapies, and immunologic system. Consequently, the development of new therapies, especially potential molecules that focus on specific viral mechanisms to block viral replication, became a critical challenge in recent decades. The Reverse Transcriptase (RT) is an RNA‐ and DNA‐dependent DNA polymerase enzyme that is responsible for transcribing viral RNA into double‐stranded DNA. Non‐nucleoside RT Inhibitors perform important role in HIV therapy, and they are responsible for inhibiting RT by blocking its allosteric site, which shows physico‐chemical properties such as high hydrophobicity and key amino acid‐to‐hydrogen bond interactions. For this reason, designing new molecules with innovative heterocycles compatible with these characteristics can provide new potential inhibitors. For example, pentacyclic heterocycles like thiazole and its derivatives like thiazolidinedione, which have physico‐chemical properties that can interact with the allosteric site of RT, can be a new perspective in designing new Non‐nucleoside RT Inhibitors. This work reviews the scientific literature concerning these compounds and can help the design of new antiviral therapeutics.
Dengue fever is one of the greatest global health crises, with millions of infections annually and no effective antiviral therapy available. The high morbidity and mortality rate, combined with the rapid spread of the virus, highlights a critical failure in the fight against the disease. In this scenario, the search for new antiviral drugs is not only necessary, but urgent. Recently, thiazolidinedione (TZD) and thiazole derivatives have emerged as potential candidates for the treatment of dengue fever, challenging the paradigms of conventional therapies. These compounds represent a radically innovative approach by integrating direct antiviral activity—through selective inhibition of the NS2B‐NS3 protease and NS5 RNA polymerase—with the modulation of the inflammatory response, a key determinant in the progression of severe disease forms.The present study offers an in‐depth and innovative analysis of the therapeutic potential of these molecules, exploring in vitro and in silico assays and pharmacokinetic improvement strategies. The results reveal that TZDs and thiazoles have high affinity for strategic viral targets, effectively interrupting the DENV replication cycle and reducing the immunopathological effects of the infection. Unlike conventional antivirals, which fail to target a single mechanism of action, these molecules offer a multifunctional and disruptive approach, potentially redefining the treatment of dengue. By consolidating new therapeutic perspectives and providing a solid basis for future preclinical and clinical investigations, this study not only contributes to the advancement of biomedical science, but also represents a crucial milestone in the fight against one of the most neglected viruses in the world.